Singapore, April 8 -- BioOra Limited, a commercial-stage cell therapy company advancing CAR-T therapies for cancer patients, and Canada-based Octane Biotech Inc., an Octane Medical Group Company, has announced the signing of a Letter of Intent (LoI) to collaborate on the co-development and deployment of advanced cell therapies using the Cocoon(R) automated cell therapy manufacturing platform. The collaboration builds upon the existing partnership through which BioOra's CD19-targeted CAR-T therapy (Atla-Cel) is produced by Octane's Cocoon Platform for patients with relapsed or refractory B-cell lymphoma in New Zealand as part of the registration trial (ENABLE-2).

Under the agreement, BioOra and Octane will work together to expand man...